Key points are not available for this paper at this time.
A new study uncovers a mechanism by which trastuzumab (Herceptin) counters the progression of cancer. The findings point to a subgroup of patients who are likely to have a response to treatment.
Pier Paolo Pandolfi (Wed,) studied this question.